Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696288 | 0.89 | HSD11B1 (0.47) | HSD11B1ADORA3NLRP3GSTO1 | |
| SCHEMBL22925487 | 0.89 | HSD11B1 (0.47) | HSD11B1ADORA3NLRP3GSTO1 | |
| SCHEMBL22925868 | 0.88 | HSD11B1 (0.46) | HSD11B1ADORA3GSK3BNLRP3CASP1 | |
| SCHEMBL22925878 | 0.82 | HSD11B1 (0.49) | HSD11B1KIF11 | |
| SCHEMBL29621154 | 0.81 | HSD11B1 (0.46) | HSD11B1VNN1 | |
| SCHEMBL22925866 | 0.81 | HSD11B1 (0.46) | HSD11B1VNN1 | |
| SCHEMBL22925658 | 0.78 | TRPV1 (0.47) | GSK3B | |
| SCHEMBL22926076 | 0.77 | HSD11B1 (0.51) | HSD11B1ADORA3P2RY14GSK3BKIF11 | |
| SCHEMBL28554860 | 0.74 | HSD11B1 (0.50) | HSD11B1ADORA3KIF11 | |
| SCHEMBL22925671 | 0.73 | HSD11B1 (0.45) | HSD11B1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | HSD11B1 843/4885ADORA3 4638/4885P2RY14 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.